Global Vutrisiran Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleosides, & Others), By Route of Administration (Injectable, Parenteral, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, & Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 - 2032

Industry: Healthcare
RELEASE DATE Apr 2023
REPORT ID SI1750
PAGES 200
REPORT FORMAT PathSoft
Request Free Sample
Description Table of Contents Scope of Report Methodology
  1. Introduction
    1. Objectives of the Study
    2. Market Definition
    3. Research Scope
  2. Research Methodology and Assumptions
  3. Executive Summary
  4. Premium Insights
    1. Porter’s Five Forces Analysis
    2. Value Chain Analysis
    3. Top Investment Pockets
      1. Market Attractiveness Analysis By Drug Class
      2. Market Attractiveness Analysis By Route of Administration
      3. Market Attractiveness Analysis By Distribution Channel
      4. Market Attractiveness Analysis By Region
    4. Industry Trends
  5. Market Dynamics
    1. Market Evaluation
    2. Drivers
      1. Rising hereditary transthyretin amyloidosis prevalence, innovative RNAi therapies, improved diagnosis
    3. Restraints
      1.  High treatment costs, limited patient awareness, stringent regulatory approval processes
    4. Opportunities
      1.  Expanding indications, emerging markets, increased healthcare spending, supportive reimbursement policies
    5. Challenges
      1. Long development timelines, competition from alternatives, manufacturing complexity, access inequities
  6. Global Vutrisiran Market Analysis and Projection, By Drug Class
    1. Segment Overview
    2. Antisense Oligonucleotide
    3. Nucleic Acids
    4. Nucleotide
    5. Nucleoside
    6. Others
  7. Global Vutrisiran Market Analysis and Projection, By Route of Administration
    1. Segment Overview
    2. Oral
    3. Injectable
    4. Subcutaneous
  8. Global Vutrisiran Market Analysis and Projection, By Distribution Channel
    1. Segment Overview
    2. Hospital Pharmacies
    3. Retail Pharmacies
    4. Online Pharmacies
    5. Others
  9. Global Vutrisiran Market Analysis and Projection, By Regional Analysis
    1. Segment Overview
    2. North America
      1. U.S.
      2. Canada
      3. Mexico
    3. Europe
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
    4. Asia-Pacific
      1. Japan
      2. China
      3. India
    5. South America
      1. Brazil
    6. Middle East and Africa
      1. UAE
      2. South Africa
  10. Global Vutrisiran Market-Competitive Landscape
    1. Overview
    2. Market Share of Key Players in the Vutrisiran Market
      1. Global Company Market Share
      2. North America Company Market Share
      3. Europe Company Market Share
      4. APAC Company Market Share
    3. Competitive Situations and Trends
      1. Coverage Launches and Developments
      2. Partnerships, Collaborations, and Agreements
      3. Mergers & Acquisitions
      4. Expansions
  11. Company Profiles
    1. Alnylam Pharmaceuticals, Inc
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    2.   Orphalan 
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    3.  AstraZeneca 
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    4.   Vivet Therapeutics 
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    5.   Pfizer Inc 
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    6.  Ultragenyx Pharmaceutical
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    7.   Valeant Pharmaceuticals International, Inc
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    8. Noble Pharma Co., Ltd.
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    9.  Merck & Co., Inc
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    10.  Teva Pharmaceuticals 
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis
    11.  Others
      1. Business Overview
      2. Company Snapshot
      3. Company Market Share Analysis
      4. Company Coverage Portfolio
      5. Recent Developments
      6. SWOT Analysis

List of Table

  1. Global Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  2. Global Antisense Oligonucleotide, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  3. Global Nucleic Acids, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  4. Global Nucleotide, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  5. Global Nucleoside, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  6. Global Others, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  7. Global Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  8. Global Oral, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  9. Global Injectable, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  10. Global Subcutaneous, Vutrisiran Market, By Region, 2024-2035(USD Billion)
  11. North America Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  12. North America Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  13. North America Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  14. U.S.  Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  15. U.S.  Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  16. U.S.  Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  17. Canada Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  18. Canada Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  19. Canada Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  20. Mexico Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  21. Mexico Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  22. Mexico Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  23. Europe Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  24. Europe Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  25. Europe Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  26. Germany Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  27. Germany Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  28. Germany Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  29. France Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  30. France Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  31. France Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  32. U.K.  Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  33. U.K.  Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  34. U.K.  Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  35. Italy Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  36. Italy Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  37. Italy Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  38. Spain Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  39. Spain Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  40. Spain Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  41. Asia Pacific Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  42. Asia Pacific Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  43. Asia Pacific Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  44. Japan Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  45. Japan Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  46. Japan Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  47. China Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  48. China Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  49. China Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  50. India Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  51. India Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  52. India Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  53. South America Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  54. South America Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  55. South America Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  56. Brazil Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  57. Brazil Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  58. Brazil Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  59. The Middle East and Africa Vutrisiran Market, By Drug Class, 2024-2035(USD   Billion)
  60. The Middle East and Africa Vutrisiran Market, By Route of Administration, 2024-2035(USD   Billion)
  61. The Middle East and Africa Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  62. UAE Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  63. UAE Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  64. UAE Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)
  65. South Africa Vutrisiran Market, By Drug Class, 2024-2035(USD Billion)
  66. South Africa Vutrisiran Market, By Route of Administration, 2024-2035(USD Billion)
  67. South Africa Vutrisiran Market, By Distribution Channel, 2024-2035(USD Billion)

List of Figures 

  1. Global Vutrisiran Market Segmentation
  2. Vutrisiran Market: Research Methodology
  3. Market Size Estimation Methodology: Bottom-Up Approach
  4. Market Size Estimation Methodology: Top-down Approach
  5. Data Triangulation
  6. Porter’s Five Forces Analysis
  7. Value Chain Analysis
  8. Top investment pocket in the Vutrisiran Market
  9. Top Winning Strategies, 2024-2035
  10. Top Winning Strategies, By Development, 2024-2035(%)
  11. Top Winning Strategies, By Company, 2024-2035
  12. Moderate Bargaining power of Buyers
  13. Moderate Bargaining power of Suppliers
  14. Moderate Bargaining power of New Entrants
  15. Low threat of Substitution
  16. High Competitive Rivalry
  17. Top Player Positioning, 2024
  18. Market Share Analysis, 2024
  19. Restraint and Drivers:  Vutrisiran Market
  20. Vutrisiran Market Segmentation, By Drug Class
  21. Vutrisiran Market For Antisense Oligonucleotide, By Region, 2024-2035 ($ Billion)
  22.  Vutrisiran Market For Nucleic Acids, By Region, 2024-2035 ($ Billion)
  23. Vutrisiran Market For Nucleotide, By Region, 2024-2035 ($ Billion)
  24. Vutrisiran Market For Nucleoside, By Region, 2024-2035 ($ Billion)
  25. Vutrisiran Market For Others, By Region, 2024-2035 ($ Billion)
  26.  Vutrisiran Market Segmentation, By Route of Administration
  27.  Vutrisiran Market For Oral, By Region, 2024-2035 ($ Billion)
  28.  Vutrisiran Market For Injectable, By Region, 2024-2035 ($ Billion)
  29. Vutrisiran Market For Subcutaneous, By Region, 2024-2035 ($ Billion)
  30. Vutrisiran Market Segmentation, By Distribution Channel
  31. Vutrisiran Market For Hospital Pharmacies, By Region, 2024-2035 ($ Billion)
  32. Vutrisiran Market For Retail Pharmacies, By Region, 2024-2035 ($ Billion)
  33. Vutrisiran Market For Online Pharmacies, By Region, 2024-2035 ($ Billion)
  34. Vutrisiran Market For Others, By Region, 2024-2035 ($ Billion)
  35. Alnylam Pharmaceuticals, Inc: Net Sales, 2024-2035 ($ Billion)
  36. Alnylam Pharmaceuticals, Inc: Revenue Share, By Segment, 2024 (%)
  37. Alnylam Pharmaceuticals, Inc: Revenue Share, By Region, 2024 (%)
  38. Orphalan: Net Sales, 2024-2035 ($ Billion)
  39. Orphalan: Revenue Share, By Segment, 2024 (%)
  40. Orphalan: Revenue Share, By Region, 2024 (%)
  41. AstraZeneca: Net Sales, 2024-2035 ($ Billion)
  42. AstraZeneca: Revenue Share, By Segment, 2024 (%)
  43. AstraZeneca: Revenue Share, By Region, 2024 (%)
  44. Vivet Therapeutics: Net Sales, 2024-2035 ($ Billion)
  45. Vivet Therapeutics: Revenue Share, By Segment, 2024 (%)
  46. Vivet Therapeutics: Revenue Share, By Region, 2024 (%)
  47. Pfizer Inc: Net Sales, 2024-2035 ($ Billion)
  48. Pfizer Inc: Revenue Share, By Segment, 2024 (%)
  49. Pfizer Inc: Revenue Share, By Region, 2024 (%)
  50. Ultragenyx Pharmaceutical: Net Sales, 2024-2035 ($ Billion)
  51. Ultragenyx Pharmaceutical: Revenue Share, By Segment, 2024 (%)
  52. Ultragenyx Pharmaceutical: Revenue Share, By Region, 2024 (%)
  53. Valeant Pharmaceuticals International, Inc: Net Sales, 2024-2035 ($ Billion)
  54. Valeant Pharmaceuticals International, Inc: Revenue Share, By Segment, 2024 (%)
  55. Valeant Pharmaceuticals International, Inc: Revenue Share, By Region, 2024 (%)
  56. Noble Pharma Co., Ltd.: Net Sales, 2024-2035 ($ Billion)
  57. Noble Pharma Co., Ltd.: Revenue Share, By Segment, 2024 (%)
  58. Noble Pharma Co., Ltd.: Revenue Share, By Region, 2024 (%)
  59. Merck & Co., Inc.: Net Sales, 2024-2035 ($ Billion)
  60. Merck & Co., Inc.: Revenue Share, By Segment, 2024 (%)
  61. Merck & Co., Inc.: Revenue Share, By Region, 2024 (%)
  62. Teva Pharmaceuticals: Net Sales, 2024-2035 ($ Billion)
  63. Teva Pharmaceuticals: Revenue Share, By Segment, 2024 (%)
  64. Teva Pharmaceuticals: Revenue Share, By Region, 2024 (%)
  65. Others: Net Sales, 2024-2035 ($ Billion)
  66. Others: Revenue Share, By Segment, 2024 (%)
  67. Others: Revenue Share, By Region, 2024 (%)

Buy Now

  • Access to only 1 person; cannot be shared; cannot be printed
  • Access for 2 to 5 users only within same department of one company
  • Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

Base Year:2022
Tables & Figures:100
Pages:200
Countries covered:16
Companies covered::20
Forecast CAGR:12.8%
Request Discount

15% Free Customization

Share your Requirements

Request Customization

We Covered in Market

  • 24/7 Analyst Support
  • Worldwide Clients
  • Tailored Insights
  • Technology Evolution
  • Competitive Intelligence
  • Custom Research
  • Syndicated Market Research
  • Market Snapshot
  • Market Segmentation
  • Growth Dynamics
  • Market Opportunities
  • Regulatory Overview
  • Innovation & Sustainability

Connect with us

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies